An end-to-end solution to maximize revenue
Successful commercialization of a product requires an end-to-end strategy that maximizes revenue by eliminating revenue leakage and compliance risk while enabling profitable revenue growth in all channels.
Revenue Cloud for Pharma helps manufacturers maximize revenue at every point in the commercialization process specifically by:
- Providing the power to optimize 100% of global revenue and the flexibility to continuously adjust throughout the entire product’s lifecycle and beyond
- Ending revenue leakage in payer and provider contract pricing and rebating processes
- Ensuring adherence to complex government pricing regulations are met
- Enabling detailed visibility into gross-to-net across all channels
Product Solutions for Pharmaceutical
Model N BPI Gross to Net
Model N BPI Gross to Net combines Model N’s trusted transaction data sets with BPI Technologies’ sophisticated gross-to-net revenue recognition tools, enabling manufacturers to achieve complete gross-to-net visibility in near-real-time at every step of the revenue lifecycle.
We Create Value for Our Customers
As the leader in Revenue Management, we serve 90+ Life Sciences customers with our innovation, collaboration, and expertise to ensure we’re providing high performance and up-to-date products. With over 900 employees across 11 global locations, we leverage our expertise to enhance the traditional cloud offering with Revenue Management as a Service (RMaaS), our SaaS delivery model, which provides our customers with the ability to focus on their business growth and innovation, while benefiting from a lower, predictable total cost of ownership.
What our customers say
“We now have an effective and measurable way to manage the channel. Model N’s CDM solution made us much more proactive in our approach to working with our partners.”
Senior Vice President, Global Channels and Operations, Cambium Networks
“Model N helps us manage our global channel so we can drive more revenue.”
Senior Manager, Worldwide Channel Management, AMD